Zepbound Cannabis Interaction Profile: What You Need to Know

What the Zepbound label says about interactions

The Zepbound prescribing information describes interactions with insulin or sulfonylureas (higher hypoglycemia risk), with oral hormonal contraceptives, and with other oral medicines [1]. For oral hormonal contraceptives, the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose escalation [1]. The oral-medicine section states that Zepbound delays gastric emptying and has the potential to affect the absorption of oral medications taken at the same time [1]. It advises caution with those medicines and monitoring of drugs that depend on threshold concentrations for efficacy or have a narrow therapeutic index, naming warfarin as the example [1]. Cannabis is not mentioned in any of these interaction sections [1].

Liver enzymes and tirzepatide

Tirzepatide is metabolized by proteolytic cleavage of its peptide backbone, beta-oxidation of its fatty diacid and amide hydrolysis, not by CYP enzymes, and the label reports low in vitro potential for tirzepatide to inhibit or induce CYP enzymes [1]. Its half-life is about 5 days, and steady state is reached after 4 weeks of weekly dosing [1].

Edibles and the gastric-emptying delay

The label puts numbers on the gastric-emptying effect using acetaminophen, an oral medicine absorbed through the gut. After a first 5 mg dose of tirzepatide, acetaminophen peak concentration fell 55% and peak time came 1 hour later; by week 6, on 15 mg, there was no meaningful effect on peak concentration or peak time, and total exposure was unchanged [1]. The label adds that the delay is largest after the first dose and diminishes over time [1].

Edible cannabis is swallowed, so the label's general statement about oral medicines is the closest relevant information. The acetaminophen data show that general effect; they are not a THC result.

Does cannabis change Zepbound's weight loss?

The label describes tirzepatide as decreasing calorie intake, likely via appetite [1]. In SURMOUNT-1, 2,539 adults with obesity or overweight and without diabetes were randomized to tirzepatide 5, 10 or 15 mg or placebo; at 72 weeks the 15 mg group lost a mean 20.9% of body weight versus 3.1% on placebo [4]. No source here compares weight outcomes between people who use cannabis and people who do not.

A 2026 review of incretin therapies and substance use notes that observational analyses have reported lower rates of cannabis use disorder with these drugs, while stating that evidence beyond alcohol and tobacco, and tirzepatide-specific evidence, remains preliminary [5].

Nausea and vomiting: the biggest overlap

Nausea is the most common adverse reaction in the Zepbound trials: 25% on 5 mg, 29% on 10 mg and 28% on 15 mg, against 8% on placebo; vomiting was 8%, 11% and 13% against 2% [1]. Any gastrointestinal adverse reaction occurred in 56% of patients on every Zepbound dose, versus 30% on placebo, and most nausea, vomiting and diarrhea happened during dose escalation and decreased over time [1]. Severe gastrointestinal reactions were reported in 1.7%, 2.5% and 3.1% on 5, 10 and 15 mg versus 1% on placebo, and the label says Zepbound is not recommended in people with severe gastroparesis [1].

Cannabis has a vomiting syndrome of its own. Cannabinoid hyperemesis syndrome is associated with cannabinoid overuse and typically presents with cyclical vomiting, diffuse abdominal pain and relief with hot showers [3]. A consensus guideline for emergency departments describes conventional antiemetics as having limited effectiveness, calls topical capsaicin a reasonable first-line option, and states that cannabis cessation is the only intervention that provides complete relief [3].

When someone on Zepbound vomits, more than one explanation is possible. The label says to discontinue Zepbound if pancreatitis is suspected, and lists possible signs as persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting [1]. A 2025 case report described a 55-year-old woman with type 2 diabetes, chronic kidney disease and prior pancreatitis who presented with severe gastrointestinal symptoms, sepsis physiology and metabolic derangement shortly after tirzepatide up-titration, in the setting of cannabis use; the authors highlighted the challenge of overlapping clinical syndromes in complex patients [2]. The report does not establish that the combination caused her illness.

In animals, CB1 receptor activation suppresses vomiting, and cannabidiol suppresses nausea and vomiting within a limited dose range in preclinical work [6]. That is laboratory evidence, not a result in people taking Zepbound.